Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study

Circulating tumor DNA analysis depicts subclonal architecture and genomic evolution of small cell lung cancer

(2018) Jingying Nong et al.   Nature Communications

Technical Validation of a Next-Generation Sequencing Assay for Detecting Clinically Relevant Levels of Breast Cancer–Related Single-Nucleotide Variants and Copy Number Variants Using Simulated Cell-Free DNA

(2017) Xin Yang et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Efficacy and safety of everolimus in Chinese metastatic HR positive, HER2 negative breast cancer patients: a real-world retrospective study

(2017) Chengcheng Gong et al.   Oncotarget

Landscape of somatic mutations in different subtypes of advanced breast cancer with circulating tumor DNA analysis

(2017) Zongbi Yi et al.   Scientific Reports

Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From BOLERO-2

(2016) Gabriel N. Hortobagyi et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular evaluation of PIK3CA gene mutation in breast cancer: determination of frequency, distribution pattern and its association with clinicopathological findings in Indian patients

(2016) Firoz Ahmad et al.   MEDICAL ONCOLOGY

Mutation distributions and clinical correlations of PIK3CA gene mutations in breast cancer

(2016) Ebubekir Dirican et al.   TUMOR BIOLOGY

Translational studies within the TAMRAD randomized GINECO trial: evidence for mTORC1 activation marker as a predictive factor for everolimus efficacy in advanced breast cancer

(2014) I. Treilleux et al.   ANNALS OF ONCOLOGY

Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†

(2014) M. Piccart et al.   ANNALS OF ONCOLOGY

The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers

(2014) Elisavet Paplomata et al.   Therapeutic Advances in Medical Oncology

Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis

(2013) Denise A. Yardley et al.   ADVANCES IN THERAPY

Activating ESR1 mutations in hormone-resistant metastatic breast cancer

(2013) Dan R Robinson et al.   NATURE GENETICS

Analysis of PIK3CA Mutations in Breast Cancer Subtypes

(2013) Ruza Arsenic et al.   APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY

mTOR inhibitors in the management of hormone receptor-positive breast cancer: the latest evidence and future directions

(2012) C. Villarreal-Garza et al.   ANNALS OF ONCOLOGY

Abstract 4485: Preclinical characterization of PWT33597, a dual inhibitor of PI3-kinase alpha and mTOR

(2012) David J. Matthews et al.   CANCER RESEARCH

PIK3CA Mutation H1047R Is Associated with Response to PI3K/AKT/mTOR Signaling Pathway Inhibitors in Early-Phase Clinical Trials

(2012) F. Janku et al.   CANCER RESEARCH

Defining biomarkers to predict sensitivity to PI3K/Akt/mTOR pathway inhibitors in breast cancer

(2012) A.M. Gonzalez-Angulo et al.   CANCER TREATMENT REVIEWS

A Multicenter Phase I Trial of PX-866, an Oral Irreversible Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Advanced Solid Tumors

(2012) D. S. Hong et al.   CLINICAL CANCER RESEARCH

mTOR inhibitors in breast cancer: A systematic review

(2012) Flora Zagouri et al.   GYNECOLOGIC ONCOLOGY

PI3K/AKT/mTOR Inhibitors in Patients With Breast and Gynecologic Malignancies HarboringPIK3CAMutations

(2012) Filip Janku et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study

(2012) Thomas Bachelot et al.   JOURNAL OF CLINICAL ONCOLOGY

Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy

(2011) Seth A. Wander et al.   JOURNAL OF CLINICAL INVESTIGATION

Prospective Study Evaluating the Impact of Tissue Confirmation of Metastatic Disease in Patients With Breast Cancer

(2011) Eitan Amir et al.   JOURNAL OF CLINICAL ONCOLOGY

“Overcoming breast cancer drug resistance with mTOR inhibitors”. Could it be a myth or a real possibility in the short-term future?

(2010) Nadia Margariti et al.   BREAST CANCER RESEARCH AND TREATMENT

Predictive Biomarkers of Sensitivity to the Phosphatidylinositol 3' Kinase Inhibitor GDC-0941 in Breast Cancer Preclinical Models

(2010) C. O'Brien et al.   CLINICAL CANCER RESEARCH

NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations

(2008) V. Serra et al.   CANCER RESEARCH

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER